|
Life Science Nation Newsletter | November 6, 2014 | Issue 87
|
|
 Life Science Investor Mandates (Oct. 29 - Nov. 5) |
| |
|
Looking Opportunistically in the Life Science Space
|
|
Seeking Early Stage Therapeutics and Devices
|
|
Seeking Early Stage European Life Science Opportunities
|
109 Investors from 20 Countries- October Mandate Roundup
|
|
The Lure of The Shipping Product, and Why It's A Compelling Opportunity: RESI Commercializing Medtech Innovation Panel Announcement
|
LSN Research Puts Boots on the Ground in Asia
READ MORE
|
|
|
|
By Lucy Parkinson, Senior Research Manager, LSN
Last week, the LSN research team closed out the first month of the last quarter, tallying and analyzing the investor mandates gathered throughout October. Our researchers spoke with 109 deal-sourcing executives last month. As usual, these investors were highly diverse, hailing from 20 countries and representing 9 investor categories; 12 of the 109 were investors from family offices and private-wealth funds. (See Figure 1.)...
|
 |
|
|
By Tom Crosby, RESI Conference Manager, LSN
 At the next RESI Conference in January, LSN will expand its Medtech Track. One of several new panels, Commercializing Medtech Innovation will focus on investors who consider later-stage opportunities, such as devices that are about to reach commercialization or those that have recently been approved and begun shipping. In keeping with the goals of the RESI Conference, this session will be compelling for earlier-stage device entrepreneurs as well, as panelists will discuss the nuances of emerging companies building relationships with investors. Moderated by David Cassak, Managing Partner at Innovation in Medtech, the audience will hear from: - Dennis Purcell, Senior Managing Partner, Aisling Capital
- Garheng Kong, Managing Partner, Healthquest Capital
- Janice Borque, Managing Director, Hercules Technology Growth Capital
- Michael Bianco, General Partner, Life Science Equity Partners
- Mark Chin, Vice President, Longitude Capital
|
|
|
|
 At the beginning of October, LSN established a presence in the Asia-Pacific region so we could increase the number of mandates from investors who are unreachable during our normal business hours. Since that initiative began, we have interviewed more than 25 deal-sourcing executives interested in the life science space. These investors are based in several countries, including Australia, China, India, Japan, Korea, New Zealand, and Singapore. A significant reason for this success could be that the investors in these countries tend to be much more responsive to cold calling, which is less common in the region, and emailing. However, when analyzing the mandates from these investors, it appears that their desire for quality deal flow from U.S. and European companies is also motivating them to share their investment criteria with us... |
|
|
|
|
|
Editors:
Nono Hu, Senior Manager, Branding & Messaging, LSN
|
|
|
|
